What is it about?
Plants in the Amaryllidaceae family possess significant medicinal value due to their diverse alkaloid and non-alkaloid metabolites, which exhibit strong antitumor, antiparasitic, antiviral, and acetylcholinesterase-inhibitory properties. A PRISMA-guided systematic review of 92 studies published between 2000 and 2025 highlights these chemical profiles and analytical methods, though further research is required to ensure safety and advance drug development.
Featured Image
Photo by James Yarema on Unsplash
Why is it important?
This excerpt highlights the clinical and pharmaceutical importance of the Amaryllidaceae plant family—renowned for producing neuroprotective compounds like galanthamine (an FDA-approved Alzheimer's treatment) as well as antitumor, antiviral, and antiparasitic leads like lycorine and haemanthamine—by consolidating a quarter-century (2000–2025) of phytochemical and analytical research through a rigorous PRISMA systematic review. Beyond traditional isoquinoline alkaloids, it emphasizes the growing role of non-alkaloid secondary metabolites and establishes a systematic framework for future drug discovery, emphasizing the critical need to optimize safety profiles, characterize chemical structures, and mitigate plant-extract toxicity to successfully transition these bioactive metabolites into safe, clinical-grade therapeutics.
Perspectives
The provided article takes a scientific, pharmacognostical, and drug-discovery perspective on the Amaryllidaceae plant family. Rather than viewing these plants strictly as decorative or traditional flora, the authors approach them as valuable biological sources of novel therapeutic compounds. Their perspective emphasizes that while traditional use and ornamental popularity highlight the plant family's importance, rigorous modern science—specifically systematic literature analysis, structural chemical profiling, and computer-aided methodologies like molecular docking—is essential to validate their pharmacological potential (such as AChE inhibition and antitumor activities) and safely translate these natural metabolites into modern medicine.
Dr Mayssaloune Ali Kanso
Beirut Arab University
Read the Original
This page is a summary of: Bioactive Secondary Metabolites of the Amaryllidaceae Family, Journal of Applied Pharmaceutical Science, May 2026, SAGE Publications,
DOI: 10.1177/22313354261427912.
You can read the full text:
Contributors
The following have contributed to this page
